CN1247247C - Apoplexy treating Chinese traditional medicine and its preparation - Google Patents
Apoplexy treating Chinese traditional medicine and its preparation Download PDFInfo
- Publication number
- CN1247247C CN1247247C CNB2003101051981A CN200310105198A CN1247247C CN 1247247 C CN1247247 C CN 1247247C CN B2003101051981 A CNB2003101051981 A CN B2003101051981A CN 200310105198 A CN200310105198 A CN 200310105198A CN 1247247 C CN1247247 C CN 1247247C
- Authority
- CN
- China
- Prior art keywords
- apoplexy
- radix
- chinese medicine
- ball
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000006011 Stroke Diseases 0.000 title claims abstract description 105
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 104
- 239000003814 drug Substances 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- 210000000582 semen Anatomy 0.000 claims description 42
- 239000000843 powder Substances 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 26
- 241000237636 Pheretima Species 0.000 claims description 25
- 241000522620 Scorpio Species 0.000 claims description 25
- 239000009490 scorpio Substances 0.000 claims description 25
- 235000012239 silicon dioxide Nutrition 0.000 claims description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- 239000006187 pill Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 238000005498 polishing Methods 0.000 claims description 8
- 229940126678 chinese medicines Drugs 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 23
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 9
- 241000270708 Testudinidae Species 0.000 abstract description 6
- 230000003925 brain function Effects 0.000 abstract description 3
- 238000007796 conventional method Methods 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 244000001632 Acorus gramineus Species 0.000 abstract 1
- 235000013073 Acorus gramineus Nutrition 0.000 abstract 1
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000189799 Asimina triloba Species 0.000 abstract 1
- 235000006264 Asimina triloba Nutrition 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 235000009467 Carica papaya Nutrition 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 235000003956 Luffa Nutrition 0.000 abstract 1
- 244000302544 Luffa aegyptiaca Species 0.000 abstract 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 abstract 1
- 244000050983 Luffa operculata Species 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 241000736199 Paeonia Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 241001233061 earthworms Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 28
- 210000004556 brain Anatomy 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- 230000017531 blood circulation Effects 0.000 description 15
- 230000037396 body weight Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 210000003677 hemocyte Anatomy 0.000 description 13
- 229940000351 hemocyte Drugs 0.000 description 13
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 12
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 12
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 12
- 230000002490 cerebral effect Effects 0.000 description 12
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 12
- 229960002646 scopolamine Drugs 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 230000004089 microcirculation Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000036541 health Effects 0.000 description 7
- 206010013786 Dry skin Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 5
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 5
- -1 Polyethylene Polymers 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229960002275 pentobarbital sodium Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229920001503 Glucan Polymers 0.000 description 4
- 206010019468 Hemiplegia Diseases 0.000 description 4
- 206010020649 Hyperkeratosis Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 231100001252 long-term toxicity Toxicity 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000003446 pia mater Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000009189 diving Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229960004526 piracetam Drugs 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FENWRHVHBZQJGW-UHFFFAOYSA-N 5-ethoxy-4-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)thiophene-2-sulfonamide Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C=1C=C(S(N)(=O)=O)SC=1OCC FENWRHVHBZQJGW-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a traditional Chinese medicine for treating apoplexy and a preparation process thereof, which belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine for treating apoplexy is composed of prepared rehmannia root, white peony root, Chinese angelica root, Chuanxiong rhizome, achyranthes root, dragon bone, tortoise plastron, red sage root, peach kernels, red peony root, earthworms, grassleaved sweetflag rhizome, tabasheer, pawpaw, buck grass, coix seed, mulberry twigs, luffa vegetable sponge, scorpion and eucommia bark as raw materials in the weight ratio of (8 to 12): (8 to 12): (3 to 7): (3 to 7): (3 to 7): (6 to 10): (3 to 7): (8 to 12): (3 to 7): (3 to 7): (3 to 7): (3 to 7): (8 to 12): (6 to 10): (4 to 8): (8 to 12): (8 to 12): (3 to 7): (1 to 5): (1 to 3). The traditional Chinese medicine for treating apoplexy can be made into any conventional oral preparation by means of the conventional method of the traditional Chinese medicine preparation. The present invention has the functions of obviously inhibiting platelet aggregation and thrombosis, improving brain functions and improving memory and has conspicuous curative effect on treating patients in the restoration stage of apoplexy and sequelae of apoplexy.
Description
Affiliated technical field
The present invention relates to a kind of Chinese medicine for the treatment of apoplexy and preparation method thereof, relating in particular to the Chinese herbal medicine is a kind of medicine for the treatment of apoplexy convalescent period and sequela of feedstock production, belongs to the field of Chinese medicines, and nomenclature of drug is a Testudinis dragon apoplexy ball.
Background technology
China's population senescence trend is obvious day by day, and there are 1,000 ten thousand stroke patients in the whole nation every year approximately, and mortality rate accounts for first of various diseases, about 890,000 people.At present, for the rescue of apoplexy at acute stage,, obtained remarkable progress owing to carried out national emergency case cooperation.But through treatment, save life person from damage, convalescent period and sequela treatment aspect remain than hang-up, and many people have stayed diseases such as " hemiplegia ", " aphasis ", have brought very big misery and inconvenience in life for patient and household thereof.Therefore, the treatment of apoplexy convalescent period and sequela, the task of top priority of real genus.At present then seldom for the medicine for the treatment of apoplexy convalescent period and sequela, the caused sequela hemiplegia of apoplexy, no matter be the hemiplegia that hemorrhagic apoplexy or cerebral thrombosis cerebral infarction are caused, investigate its clinical characters, main pathology is that liver-yin insufficiency of blood, the mistake of muscle arteries and veins are moistened, the wind sun is interior moving, the expectorant stasis of blood of holding concurrently is handed over resistance, clinical manifestation sees that affected limb spasm of muscles and vessels, contracture, joint stuffiness, muscle are twitched, the companion sees dizziness, aphasia or the limb aching pain discomfort is arranged more, the course of disease for a long time gradually the person can have muscle skinny, emotion being irritable and getting angry easily etc.And the medicine of general treatment apoplexy though certain therapeutical effect is arranged, for anticoagulant and thrombosis, improves brain function, and aspect such as improve one's memory still can not be satisfactory.
Summary of the invention
Technical problem to be solved by this invention provides a kind of Chinese medicine for the treatment of apoplexy and preparation method thereof, it has solved the problem of paralytic aspect convalescent period and sequela treatment, it had both had the cerebral blood flow increasing amount, reduce vascular permeability, microcirculation improvement improves anti-ischemia, the anoxia ability of cerebral tissue, and alleviates the pathological change behind the ischemia, reduce brain water content, alleviate effects such as cerebral edema; Simultaneously have obvious anticoagulant and thrombosis again, improve brain function, the effect that improves one's memory.
The weight ratio scope of each raw material of the present invention is to carry out a large amount of groping through the inventor to draw with experimental summary, and the weight ratio of each raw material all has curative effect preferably at following weight range.The present invention adopts following 20 kinds of medicines to make up, and makes each efficacy of drugs produce synergism these drug regimens, thereby can effectively treat apoplexy.
It is to be made of by weight following raw material: Radix Rehmanniae Preparata: the Radix Paeoniae Alba: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Radix Achyranthis Bidentatae: Os Draconis: Carapax et Plastrum Testudinis: Radix Salviae Miltiorrhizae: Semen Persicae: Radix Paeoniae Rubra: Pheretima: Rhizoma Acori Graminei: Concretio Silicea Bambusae: Fructus Chaenomelis: Herba Lycopodii: Semen Coicis: Ramulus Mori: Retinervus Luffae Fructus: Scorpio: Cortex Eucommiae carbon=, (8-12):, (8-12):, (3-7):, (3-7):, (3-7):, (6-10):, (3-7):, (8-12):, (3-7):, (3-7):, (3-7):, (3-7):, (8-12):, (6-10):, (4-8):, (8-12):, (8-12):, (3-7):, (1-5):, (1-3).
The present invention can adopt the conventional method of Chinese medicine preparation to make any conventional oral preparations.For example these crude drug pulverize mix homogeneously can be made powder takes after mixing it with water, also can make tablet etc.But the watered pill is convenient to swallow, and is difficult for the moisture absorption again, helps keeping and stores, and because of watered pill binding agent is a water, and has a certain amount of medical material fine powder to be used as medicine, and is easier to molten diffusing absorption behind the clothes, and produce effects is very fast, the preparation technology of the presents emphasis statement watered pill.But these can not be used to limit protection scope of the present invention.
Its preparation technology is as follows:
A. above 20 flavor medicines are got the Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, the Scorpio that meet the above-mentioned raw materials proportioning and are ground into coarse powder;
B. get the Radix Rehmanniae Preparata, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Achyranthis Bidentatae, Os Draconis, Carapax et Plastrum Testudinis, Radix Salviae Miltiorrhizae, Semen Persicae, Radix Paeoniae Rubra, Fructus Chaenomelis, Herba Lycopodii, Ramulus Mori, Retinervus Luffae Fructus ten four Chinese medicines that meet the above-mentioned raw materials proportioning and decoct with water several times, filter to get filtrate at every turn;
C. the filtrate with above-mentioned each decoction gained merges, and is concentrated into thick paste, relative density 1.28-1.30 (50-60 ℃);
D. in above-mentioned thick paste, add Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, Scorpio five kinds of Chinese medicine coarse powder, mixing, drying is ground into fine powder, uses water pill, 65-95 ℃ of drying;
E. use the polishing of Cortex Eucommiae carbon coating, promptly.
Preferred feedstock ratio of the present invention is: Radix Rehmanniae Preparata: the Radix Paeoniae Alba: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Radix Achyranthis Bidentatae: Os Draconis: Carapax et Plastrum Testudinis: Radix Salviae Miltiorrhizae: Semen Persicae: Radix Paeoniae Rubra: Pheretima: Rhizoma Acori Graminei: Concretio Silicea Bambusae: Fructus Chaenomelis: Herba Lycopodii: Semen Coicis: Ramulus Mori: Retinervus Luffae Fructus: Scorpio: Cortex Eucommiae carbon=10: 10: 5: 5: 5: 8: 5: 10: 5: 5: 5: 5: 10: 8: 6: 10: 10: 5: 3: 2.
Preferred feedstock preparation technology is as follows:
A. above 20 flavor medicines are got the Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, the Scorpio that meet the above-mentioned raw materials proportioning and are ground into coarse powder;
B. get Radix Rehmanniae Preparata, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Achyranthis Bidentatae, Os Draconis, Carapax et Plastrum Testudinis, Radix Salviae Miltiorrhizae, Semen Persicae, Radix Paeoniae Rubra, Fructus Chaenomelis, Herba Lycopodii, Ramulus Mori, Retinervus Luffae Fructus and decoct with water secondary, with the water of 6 times of amounts, decocted 2 hours for the first time, filtration; With the water of 5 times of amounts, decocted 1.5 hours for the second time, filter;
C. the filtrate with above-mentioned decoction gained merges, and is concentrated into thick paste, relative density 1.29 (55 ℃);
D. in above-mentioned thick paste, add Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, Scorpio five kinds of Chinese medicine coarse powder, mixing, drying is ground into fine powder, uses water pill, 6595 ℃ of dryings;
E. use the polishing of Cortex Eucommiae carbon coating, that is, and the heavy 5g of per 30 balls.
The present invention has following advantage:
The present invention is to the treatment of apoplexy, and the improvement of the recovery of traditional Chinese medical science disease, hemorheology, platelet aggregation index all has tangible effect.The present invention has nourishing the liver and kidney, suppressing hyper-yang to eliminate wind, gentle nourishing muscle and tendon arteries and veins, blood circulation promoting and blood stasis dispelling, the effect of eleminating phlegm and freeing channels.Cure mainly the hemiplegia, crooked mouth and tongue, stiff tongue and retardation in speech, the hemianesthesia that cause by wind-phlegm blood stasis, numbness resistance venation and stirring of wind due to deficiency of YIN card, have a dizzy spell or irritated insomnia, vertigo and tinnitus, feverish sensation in the palms and soles are the apoplexy patient of main clinical manifestation; to the wind-phlegm blood stasis, the traditional Chinese medical science disease of numbness resistance venation and stirring of wind due to deficiency of YIN card unusually all has the obvious treatment effect.Pill volume of the present invention is little, and is smooth with Cortex Eucommiae carbon coating surface compact, both has been convenient to swallow, and is difficult for the moisture absorption again, helps keeping and stores.Because of its binding agent is a water, and have a certain amount of medical material fine powder to be used as medicine, be easier to molten diffusing absorption behind the clothes, produce effects is fast.
Description of drawings
Fig. 1 is preparation technology's flow diagram of the present invention.
The specific embodiment
Below routine by experiment beneficial effect of further setting forth medicine of the present invention (to call Testudinis dragon apoplexy ball in the following text), these experiments comprise pharmacodynamic experiment and long term toxicity test.
(experimental example 1)
The research of Testudinis dragon apoplexy ball long term toxicity test
Testudinis dragon apoplexy ball cures mainly apoplexy, makes an appraisal for this medicine is had no side effect, and to guarantee clinical drug safety, by the pertinent regulations of " provisions for new drugs approval ", we have carried out long term toxicity test to Testudinis dragon apoplexy ball, now the result are reported as follows:
One, material
1, animal: SD kind rat, body weight 150-180 gram.Male and female half and half.Available from state plan fertility scientific research institution animal center.
2, medicine: Testudinis dragon apoplexy ball is provided by Shenyang Traditional Chinese Medicine Factory.
3, route of administration: gastric infusion.
Two, method:
1, rat is 60, and male and female half and half are divided into three groups at random, each 10 of every group of male and female.
2, dosage: heavy dose of group: 37.5g crude drug/kg (dry extract 14.76g/kg is equivalent to 50 times of clinical consumption), small dose group: 18.75g crude drug/kg (dry extract 7.38g/kg is equivalent to 25 times of clinical consumption), gastric infusion, once a day, successive administration 5 months.
3, experimental arrangement: observe the general situation of animal, variations such as behavior body weight.Every administration claimed a body weight in one month, according to the corresponding increase dose of body weight.Each component another name is heavy after five months, and abdominal aortic blood is checked biochemical indicators such as routine blood test, hepatic and renal function.Core, liver, spleen, lung, kidney weigh, calculate organ index, and get internal organs such as above-mentioned tissue and stomach, large intestine, small intestinal, adrenal gland and carry out pathological examination.
Three, result:
1, general situation: the appetite of each dosage group and control rats after the medication, all no abnormal change such as activity.
2, to the influence of body weight: every month, each component another name heavily the results are shown in Table 1
Table 1 Testudinis dragon apoplexy ball is to the influence of rat body weight (X ± SD)
| Before the administration (g) | 1 month | 2 months | 3 months | 4 months | 5 months | |
| Contrast is heavy dose of low dose of | 159.66±20.27 160.55±39.13 167.50±47.67 | 234.6±27.56 243.5±32.39 247.6±26.56 | 281.9±23.86 286.3±37.54 284.3±36.90 | 320.8±22.86 328.4±30.43 334.6±23.89 | 356.6±32.81 358.7±29.04 360.4±38.54 | 384.9±28.33 399.0±30.37 384.8±43.54 |
Relatively there is not significant difference by visible each treated animal body weight gain of table 1 and normal control group.P＞0.05。
3, to the influence of rat peripheral hemogram: the results are shown in Table 2
Table 2 Testudinis dragon apoplexy ball is to the influence of rat peripheral hemogram (X ± SD)
| (ten thousand/mm of leukocyte 2) | Classification (%) | Hemoglobin (g/%) | ||
| Neutral | Lymph | |||
| Contrast is heavy dose of low dose of | 0.69±0.28 0.61±0.21 0.56±0.16 | 27.5±5.89 27.3±3.35 28.5±6.40 | 72.5±5.89 72.7±3.35 71.5±6.40 | 15.46±1.98 15.19±1.44 14.35±1.57 |
By visible each the dosage group of this medicine of table 2 rat hemoglobin, leukocyte and classification are not made significant difference.P＞0.05
4, to the influence of liver, renal function: abdominal aortic blood is surveyed ALT, AST (enzyme coupling method) and BUN (urase-Na Shi reagent explicit representation).The results are shown in Table 3.
Table 3 Testudinis dragon apoplexy ball is to the influence of rats'liver renal function (X ± SD)
| ALT(umol/sh) | AST(umol/sh) | BUN(mmol/l) | |
| The heavy dose of group of matched group small dose group | 0.11±0.02 0.10±0.02 0.10±0.01 | 0.61±0.08 0.60±0.08 0.62±0.06 | 7.26±1.37 7.61±1.18 7.23±1.18 |
By each dosage group of the visible Testudinis dragon of table 3 apoplexy ball the rats'liver renal function all there is not influence.P＞0.05
5, each internal organs pathological examination: dissect animal, all no abnormal change of Rats Organs and Tissues is respectively organized in perusal, cores, liver, spleen, lung, kidney weigh respectively, calculates organ index, the results are shown in Table 4.
Table 4 Testudinis dragon apoplexy ball is to the influence of organ index (X ± SD)
| The heart (%) | Liver (%) | Spleen (%) | Lung (%) | Kidney (%) | |
| Contrast is heavy dose of low dose of | 0.36±0.14 0.35±0.11 0.36±0.22 | 4.47±0.52 4.39±0.48 4.46±0.37 | 0.16±0.04 0.18±0.05 0.17±0.09 | 0.66±0.12 0.64±0.15 0.66±0.06 | 0.85±0.14 0.84±0.11 0.85±0.09 |
By table 4 as seen, this medicine does not have the obvious P of influence＞0.05 to each group Rats Organs and Tissues index
With above-mentioned internal organs and brain, stomach, large intestine, small intestinal, adrenal gland etc. with formalin solution fix, waxdip, embedding, section, dyeing, under mirror, carry out pathological examination.
Internal organs such as matched group and each administration treated animal brain, the heart, liver, spleen, lung, adrenal gland, stomach, large intestine, small intestinal reach under the mirror observation substantially all not to be had pathology and changes, and the result is as follows:
The result shows: this medicine does not have remarkable toxicity to each internal organs.
Four, conclusion
This experimental result shows, Testudinis dragon apoplexy ball is by 25 and 50 times of clinical consumption, and successive administration 5 months does not have obvious influence and toxicity to growth, body weight, hemogram, the hepatic and renal function of animal, internal organs pathological examination also no abnormality seen changes, and as seen this medicine can be used safely in clinical.
(experimental example 2)
Testudinis dragon apoplexy ball pharmacodynamic study
A. Testudinis dragon apoplexy ball to rat cerebral ischemia after the research of therapeutical effect
One, material
1, animal: 50 of Wistar kind rats, male, body weight 228.1 ± 25.1 grams.Provide by the court animal housing.
2, medicine: Testudinis dragon apoplexy ball, 2.54g crude drug/g extracts dry extract, and Shenyang Traditional Chinese Medicine Factory provides; HUATUO ZAIZAO WAN, Qixing Pharmaceutical Factory of Guangzhou, 931301; Scotcil, North China Pharmaceutical Factory 9211410; Pentobarbital sodium, Shanghai chemistry trial-production purchasing and supply station packing factory, 86-01-22.
Two, method
Animal is with pentobarbital sodium (45mg/kg) intraperitoneal anesthesia, separate bilateral common carotid arteries (the about 2cm of length), the experimental thrombus in vivo of BT87-2 type is formed the stimulating electrode of analyzer and temperature sensor hook on tremulous pulse, continue to stimulate blood vessel wall 7 minutes with the 1.5mA unidirectional current, use the variations in temperature and the thrombosis situation of temperature sensor monitors blood vessel surface simultaneously, after forming the bilateral thrombosis, sew up wound, intramuscular injection scotcil (40U/Kg).Postoperative begins administration next day.
Animal is divided into 5 groups at random, sham operated rats (not modeling type), model group, HUATUO ZAIZAO WAN group (3g/kg), two dosage groups of Testudinis dragon apoplexy ball (10 and the 4g crude drug/Kg).
Each administration treated animal gastric infusion every day once continues a week, coordinates to test in one hour after the last administration, then sacrificed by decapitation.Win brain and bilateral common carotid arteries place thrombosis, weighing thrombus weight and cutaneous horn are heavy, and brain was placed 100 ℃ of constant temperature roasters dry 48 hours, and the weighing brain stem is heavy, and calculates cerebral index and brain water content, and the result all carries out statistical procedures (t check).
The heavy ÷ body weight of cerebral index=cutaneous horn * 100%
Brain water content=(cutaneous horn weight-brain stem is heavy) ÷ cutaneous horn heavy * 100%
The result
Table Testudinis dragon apoplexy ball is to the influence of rat cerebral ischemia
| Grouping | Dosage | N | Coordinate experiment (s) | Thrombus weight (g) | Cerebral index (%) | Brain water content |
| The heavy dose of group of sham operated rats model group HUATUO ZAIZAO WAN group apoplexy health apoplexy health small dose group | 3.0g/kg 10.0g/kg 4.0g/kg | 10 10 10 10 10 | 48.20±14.28 10.00±8.01 ## 24.40±10.55 ** 24.20±18.08 * 17.50±8.07 | 0.0000±0.0000 0.0132±0.0036 ## 0.0102±0.0029 0.0104±0.0023 0.0105±0.0017 | 0.565±0.052 0.623±0.060 # 0.598±0.040 0.560±0.067 * 0.575±0.073 | 78.565±0.372 79.034±0.284 ## 78.729±0.312 * 78.811±0.540 78.945±0.507 |
#, ##: compare P＜0.05, P＜0.01 with sham operated rats
*, * *: compare P＜0.05, P＜0.01 with model group
One, coordinates experiment
By table as seen, the model group animal runner time obviously shortens, and with sham operated rats significant difference (P＜0.01) is arranged relatively; Testudinis dragon apoplexy heavy dose of group runner time of ball obviously prolongs, and with model group significant difference (P＜0.05) is arranged relatively; Small dose group does not have obvious influence; Also there is prolongation the HUATUO ZAIZAO WAN group runner time, with model group significant difference (P＜0.01) is arranged relatively.
Two, to the influence of thrombus weight
By table as seen, tangible thrombosis is arranged in the model group common carotid artery, significant difference (P＜0.01) is relatively arranged with sham operated rats; Testudinis dragon two dosage groups of apoplexy ball and positive drug HUATUO ZAIZAO WAN group thrombus weight and model group relatively have the trend of alleviating, but there was no significant difference.
Three, to the influence of cerebral index and brain water content
By table as seen, model group cerebral index and brain water content obviously increase, and with sham operated rats significant difference (P＜0.05, P＜0.01) are arranged relatively; The heavy dose of group of Testudinis dragon apoplexy ball cerebral index obviously alleviates, and with model group significant difference (P＜0.05) is arranged relatively, and brain water content is also seen effect trend, the rarely seen trend that alleviates of small dose group cerebral index and brain water content; HUATUO ZAIZAO WAN group cerebral index has the trend of alleviating, but does not have significant difference, and brain water content then obviously reduces, and with model group significant difference (P＜0.01) is arranged relatively.
Conclusion
The clinical treatment that is used for apoplexy of Testudinis dragon apoplexy ball.This experiment causes ischemia model with the bilateral common carotid arteries thrombosis, and showing as brain water content and cerebral index increases, and the coordination exercise ability reduces.The therapeutic administration is adopted in experiment, causes cerebral ischemia earlier, and then administration is to observe the effect of medicine.
Practice result confirms that model group animal brain index and brain water content obviously increase, and is higher than normal group animal (sham operated rats) coordination exercise function and reduces, and shows as typical symptoms of cerebral ischemia.Testudinis dragon apoplexy ball group thrombus weight has the trend of alleviating, and cerebral index obviously reduces, and the coordination exercise time obviously prolongs, and symptom is obviously improved.
Testudinis dragon apoplexy ball can obviously improve experimental cerebral ischemia, and no matter preventive administration, or therapeutic administration all has clear and definite therapeutical effect.
B, Testudinis dragon apoplexy ball is to the influence of rat brain microcirculation disturbance
Materials and methods
One, medicine: Testudinis dragon apoplexy ball, HUATUO ZAIZAO WAN, glucosan, normal saline, pentobarbital sodium.
Two, animal: 40 of Wistar kind rat, male and female dual-purpose, body weight 250-350 gram.
Three, method: animal is divided into four groups at random, anaesthetizes with 0.6% pentobarbital sodium (0.75ml/100g) intraperitoneal administration.Open skull and expose the about 5mm * 5mm in Interhemispheric volume top, under the irradiation of cold light source 45, amplify 40 times with XIL-01 type microscope and observe the pia mater encephali microcirculation, separate a side femoral vein and inject 10% glucosan (3ml/kg), to form the pia mater encephali microcirculation disturbance.Test medicine after 20 minutes again, observed following index in same field of view in 20 minutes before medicine and behind the medicine.
1, blood flow rate: be divided into 5 grades.
0 grade: as seen blood capillary is not passed through but there is the blood cell; The I level: visible hemocyte in the blood capillary, occur hemocyte sometimes and assemble agglomeratingly, negligible amounts is pushed ahead gradually, and in time, advance in the stopping time; The II level: hemocyte is full of tube chamber in the blood capillary, slowly flows forward; The III level: hemocyte is full of tube chamber, flow to be line style, but mirror can be told the hemocyte in flowing down; The IV level: hemocyte can not differentiated in the blood capillary, and flowing velocity is exceedingly fast.
2, blood fluidised form: be divided into 5 grades.
0 grade: (-), achroacyte is assembled; The I level: (+), 2-3 hemocyte is gathered into fine graininess, do not influence blood flow rate; The II level: (++), 4-6 hemocyte is gathered into the coarse granule shape; The III level: (+++), hemocyte is gathered into lumps and influences blood flow rate.The IV level: (++ ++), blood flow stops or forming microthrombus.
Statistical method adopts grade preface value method.
The result
1, blood flow rate: blood flow rate is not seen notable difference (P＞0.05) before matched group and each the administration group medicine.The saline group is not seen change after the administration: positive drug HUATUO ZAIZAO WAN group and the visible flow velocity of the heavy dose of group of Testudinis dragon apoplexy ball make moderate progress, and with matched group significant difference (P＜0.05) are arranged relatively; Testudinis dragon apoplexy ball small dose group flow velocity is not seen improvement.The results are shown in Table 1.
2, blood fluidised form: the blood fluidised form does not have notable difference (P＞0.05) before matched group and the administration group medicine, and improvement is not seen in the gathering of saline group hemocyte after the administration; Testudinis dragon apoplexy ball heavy dose and HUATUO ZAIZAO WAN medicine bleeding from anus cell aggregation degree alleviate, and with matched group significance (P＜0.05) are arranged relatively, and Testudinis dragon apoplexy ball small dose group is not seen obvious improvement.See Table 2.
The influence of table 1 pair rat's pial microcirculation blood flow velocity
| Group | Dosage (g/kg) | Number of animals (only) | Classification | The P value | |||
| 1 | 1.5 | 2 | 2.5 | ||||
| Tortoise dragon apoplexy ball group behind big group of big group of prechelonian dragon of the medicine control group huatuo zaizao pill group tortoise dragon apoplexy ball apoplexy ball group medicine control group huatuo zaizao pill group tortoise dragon apoplexy ball | 3 10 4 | 10 10 10 10 10 10 10 10 | 1 1 1 2 1 1 | 4 5 5 3 5 4 5 3 | 5 4 4 4 4 3 3 5 | 1 3 2 1 | ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＜0.05 ＜0.05 ＞0.05 |
The influence of table 2 pair rat's pial microcirculation blood fluidised form
| Group | Dosage (g/kg) | Number of animals (only) | Classification | The P value | |||
| 1.5 | 2 | 2.5 | 3 | ||||
| Big group of big group of prechelonian dragon of medicine control group huatuo zaizao pill group tortoise dragon apoplexy ball apoplexy ball group medicine control group huatuo zaizao pill group tortoise dragon apoplexy ball | 3 10 | 10 10 10 10 10 10 10 | 1 1 1 2 1 4 6 | 5 5 5 4 5 5 2 | 2 2 1 4 2 1 2 | 2 2 3 2 | ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＜0.05 ＜0.05 |
| The imperial apoplexy ball of back Testudinis group | 4 | 10 | 2 | 5 | 2 | ＞0.05 |
The result shows that the heavy dose of group of Testudinis dragon apoplexy ball can make the microcirculatory velocity of blood flow of pia mater encephali accelerate, and the blood fluidised form is obviously improved, and the hemocyte aggregation extent obviously alleviates, and relatively is remarkable difference with matched group.
Conclusion
The intravenous injection of macromolecule glucosan can cause animal multisystem microcirculation disturbance, and this experiment forms the rat's pial model of microcirculation obstacle with glucosan, shows as blood flow rate and slows down, and hemocyte is assembled.
After matched group gave normal saline, velocity of blood flow and blood fluidised form there is no improvement.HUATUO ZAIZAO WAN and the administration of the heavy dose of group of Testudinis dragon apoplexy ball are after 20 minutes, and blood flow rate is accelerated.The blood fluidised form is obviously improved, and the hemocyte aggregation extent obviously alleviates.
Facts have proved that Testudinis dragon apoplexy ball has the effect that improves the animal brain microcirculation disturbance, blood flow rate and blood fluidised form are improved, thereby improve the blood supply oxygen supply of cerebral tissue and play therapeutical effect.
The research that C, Testudinis dragon apoplexy ball treated in vitro influence the rabbit platelet aggregation
Materials and methods
One, material
(1) medicine Testudinis dragon apoplexy ball, HUATUO ZAIZAO WAN, sterile saline, arachidonic acid.
(2) instrument BS631 type platelet aggregation instrument, Beijing biochemical instrument factory product.
(3) large ear rabbit is planted by the male New Zealand of animal health, and body weight is 2.0-3.0kg, purchases the animal housing in Military Medical Science Institute, raises in the court animal housing to be used for experiment a week.
Two, method
(1) PRP prepare rabbit with pentobarbital sodium (30mg/kg) anaesthetize through ear vein, cut the abdominal cavity and expose ventral aorta, get blood with the puncture of silication syringe, with 3.8% sodium citrate solution anticoagulant (blood: anticoagulant=9: 1), centrifugal 8 minutes of 200 * g, drawing supernatant partly is platelet rich plasma, centrifugal 15 minutes of remainder 2200 * g, and getting supernatant partly is that platelet count is 4.0 * 10 in the platelet poor plasma
5/ mm
3About.
(2) observation and analytical method adopt improvement BornShi turbidimetry
(1-2)Put the opacity tube that fills 0.45mlPRP, a little bar magnet and treat reagent or normal saline in right amount in platelet aggregation instrument, 37 ℃ of insulated and stirred 1 minute mix up baseline, add 5mg/mlAAlOul and induce gathering.According to the influence of the gathering tracing analysis medicine of being traced on the monitor to the poly-property of platelet.By following formula
(2)Calculate aggregation rate and suppression ratio:
The result
Testudinis dragon apoplexy ball and each three dosage group platelet aggregation rate of HUATUO ZAIZAO WAN all are starkly lower than normal saline group (P＜0.01) and are good dose-effect relationship.And also there is good dose-effect relationship between suppression ratio.Find out also simultaneously that the effect of Testudinis dragon apoplexy ball anticoagulant is better than HUATUO ZAIZAO WAN.The results are shown in subordinate list.
Subordinate list Testudinis dragon apoplexy ball is to the influence of the inductive rabbit platelet aggregation of AA
(X±SD％，n＝6)
| The medicine mediating recipe | Aggregation rate (%) | Suppression ratio (%) | |
| Normal saline apoplexy health HUATUO ZAIZAO WAN | 25mg crude drug/ml 35mg crude drug/ml 50mg crude drug/ml 25mg/ml 35mg/ml 50mg/ml | 60.9±1.7 32.0±9.3※ 20.4±8.1※ 0 49.0±5.3※ 32.4±5.4※ 16.1±3.5※ | 47.9±13.8 68.6±12.4 100 19.6±7.6 49.5±8.9 74.6±6.9 |
Annotate: ※ P＜0.01
Conclusion
This experimental result shows that Testudinis dragon apoplexy ball and HUATUO ZAIZAO WAN all can suppress the inductive rabbit platelet aggregation of AA, and this effect is good dose-effect relationship.Dosage is big more, and depression effect is strong more.The effect of Testudinis dragon apoplexy ball anticoagulant is better than HUATUO ZAIZAO WAN.
The influence that D, Testudinis dragon apoplexy ball form rat suppository
Materials and methods
One, material:
(1) medicine: Testudinis dragon apoplexy ball, HUATUO ZAIZAO WAN, normal saline.
(2) animal: 70 of SD rats, body weight are 180-200g male and female half and half.
(3) instrument: extracorporeal thrombosis forming device: the SDZ-A1 type, electronic machine two factories in jiangsu wuxi county produce.
Two, method: the healthy SD rat is divided into 7 groups at random.
This experiment is to dynamic observe the thrombosis overall process.With blood flow state in the analogue body in blood ex-vivo and the external rotating ring, under the hydrodynamic effect effect, form thrombosis.This thrombosis that forms under blood flow is in flow regime, its structure is very similar to the interior thrombosis that forms of body
(1)
(1) simulated conditions:
Polyethylene bore 4.0mm, long 240mm, rotating ring radius are 30.0mm, rotating ring and horizontal sextant angle 74.0 degree, the rotating ring rotating speed is 17 ± 1 rev/mins, be 10 minutes observing time, 37 ℃ of experimental temperatures.
(2) blood sample pinching:
Rat clings to than sodium (30mg/kg) intraperitoneal injection of anesthesia with penta, cut the abdominal cavity and expose ventral aorta, get blood 2ml (being sure not to be with bubble) with the puncture of silication syringe, injection at once contains in the rotating ring of 0.2ml medicinal liquid or normal saline, and the blood volume of injection should be full of rotating ring (1.8ml) below 1/2.The time that begins to rotate from blood injection syringe to rotating ring should be in 90 seconds.
(3) observational technique:
After the rotating ring rotation, tube wall is mobile relatively on certain equilbrium position for the blood post in the ring, observes and read the preceding residing angle position of concave surface of blood post.Thrombosis occurs in the relative tube wall process of flowing of blood post, thrombotic process is
(2): the platelet particle at first occurs, " snowstorm " the same phenomenon takes place thereupon, rotate beginning to above-mentioned phenomenon from rotating ring and occur, be the platelet aggregation time.Then platelet thrombus forms gradually, and then Fibrinogen is transformed into fibrin and is connected formation fibrin post on the platelet thrombus, constantly increases at this stage fiber albumen bolt, and thrombosis angle of living in also constantly changes.Carry out when complete when thrombosis, angle no longer changes, and stops operating after 10 minutes, and inclining thrombosis, measures its length, and the thrombosis bar was put 80 ℃ of baking boxs roasting 4 hours, claims its dry weight after the constant weight.
The result
One, to the influence of thrombus length.
Testudinis dragon apoplexy ball is to the influence of rats in vitro thrombosis length: the results are shown in Table 1
Table 1 Testudinis dragon apoplexy ball is to the influence of rats in vitro thrombosis length (X ± SD)
| Medicine | Concentration ※ | The example number | Thrombosis length (mm) | P |
| NS apoplexy health HUATUO ZAIZAO WAN | 12.5mg/ml 25mg/ml 50mg/ml 12.5mg/ml 25mg/ml 50mg/ml | 10 10 10 10 10 10 10 | 21.2±1.13 17.3±2.11 14.8±1.03 10.8±1.65 16.0±1.26 13.8±1.75 9.3±1.56 | ＜0.05 ＜0.05 ＜0.05 ＞0.05 ＞0.05 ＞0.05 |
※ concentration: be final concentration in the rotating ring.
As seen from the above table, the thrombus length of each dosage group of Testudinis dragon apoplexy ball is shorter than the external thrombus of NS group, and more obvious along with the increase of concentration, illustrates that Testudinis dragon apoplexy ball has the shortening effect to rats in vitro thrombosis length, and good dose-effect relationship is arranged.HUATUO ZAIZAO WAN also has the shortening effect to rats in vitro thrombosis length.
E, Testudinis dragon apoplexy ball influence scopolamine induced mice dysmnesia
One, materials and methods
1, medicine: Testudinis dragon apoplexy ball, HUATUO ZAIZAO WAN, piracetam.
2, animal: Kunming kind white mice, male, body weight 18-22 gram is purchased the animal institute in the Chinese Academy of Sciences.
3, method:
[1,2,3]Mice is divided into 7 groups at random, and every group of 10-12 only.＜1〉normal control group;＜2〉scopolamine group (0.005g/kg);＜3〉piracetam group (0.4g/kg);＜4〉HUATUO ZAIZAO WAN group (10g/kg);＜5〉the Testudinis dragon apoplexy heavy dose of group of ball (10g/kg);＜6〉dosage group (5g/kg) in the Testudinis dragon apoplexy ball;＜7〉Testudinis dragon apoplexy ball small dose group (2.5g/kg).The equal gastric infusion of each administration group, normal control group and scopolamine group give the equivalent distilled water, once a day, continuous seven days.After the last administration 50 minutes,＜2 〉-＜7〉group every mouse subcutaneous injection hydrogen bromine scopolamine 5mg/kg cause memory acquisition disturbance, and after 10 minutes, the training of beginning diving tower method was subjected to shock count (errors number) in the test animal 3min after 24 hours.Relatively reach statistical procedures between organizing.
Two, result
This experiment causes the memory acquisition disturbance model by to the mouse subcutaneous injection scopolamine, the results are shown in Table.Three dosage groups of Testudinis dragon apoplexy ball errors number all has minimizing in various degree, and wherein heavy dose of group errors number is 0.82 ± 0.75 significant difference relatively to be arranged, P＜0.05 with scopolamine group 1.60 ± 0.80.The have some improvement ability of learning and memory of little mouse of Testudinis dragon apoplexy ball is described, the mouse memory acquired disturbance is had protective effect.Piracetam group errors number is compared with scopolamine and is obviously reduced P＜0.05; HUATUO ZAIZAO WAN is to the obviously influence of mice diving tower experiment nothing.
Table: Testudinis dragon apoplexy ball is to the influence of memory acquisition disturbance due to the scopolamine: (X ± SD)
| Group | Dosage (g/kg) | Scopolamine (g/kg) | Number of animals (only) | Errors number (inferior) |
| Dosage group apoplexy health small dose group in the heavy dose of group of the normal control group scopolamine group piracetam group apoplexy health apoplexy health | 0.4 10 5 2.5 | 0.005 0.005 0.005 0.005 0.005 | 10 10 11 11 11 12 | 0.10±0.30 1.60±0.80 △△△ 0.64±0.81 ※ 0.82±0.75 ※ 1.09±0.70 0.92±0.79 |
Annotate: compare with the normal control group △ △ △＜0.001
Compare with the scopolamine group ※ P＜0.05
Three, conclusion
Experiment showed, that Testudinis dragon apoplexy ball can improve the ability of learning and memory of little mouse, scopolamine is caused that mouse memory obtains to have the certain protection effect, and similar to the effect of piracetam.
Embodiment one
A kind of Chinese medicine (Testudinis dragon apoplexy ball) for the treatment of apoplexy of the present invention is to be made of by weight following preferred feedstock: Radix Rehmanniae Preparata: the Radix Paeoniae Alba: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Radix Achyranthis Bidentatae: Os Draconis: Carapax et Plastrum Testudinis: Radix Salviae Miltiorrhizae: Semen Persicae: Radix Paeoniae Rubra: Pheretima: Rhizoma Acori Graminei: Concretio Silicea Bambusae: Fructus Chaenomelis: Herba Lycopodii: Semen Coicis: Ramulus Mori: Retinervus Luffae Fructus: Scorpio: Cortex Eucommiae carbon=8: 8: 3: 3: 3: 6: 3: 8: 3: 3: 3: 3: 8: 6: 4: 8: 8: 3: 1: 1.
Its preparation technology following (Fig. 1):
A. above 20 flavor medicines are got Concretio Silicea Bambusae 32g, Rhizoma Acori Graminei 12g, Semen Coicis 32g, Pheretima 12g, Scorpio 4g is ground into coarse powder;
B. get Radix Rehmanniae Preparata 32g, Radix Paeoniae Alba 32g, Radix Angelicae Sinensis 12g, Rhizoma Chuanxiong 12g, Radix Achyranthis Bidentatae 12g, Os Draconis 24g, Carapax et Plastrum Testudinis 12g, Radix Salviae Miltiorrhizae 32g, Semen Persicae 12g, Radix Paeoniae Rubra 12g, Fructus Chaenomelis 24g, Herba Lycopodii 16g, Ramulus Mori 32g, Retinervus Luffae Fructus 16g decoct with water secondary, for the first time with the water of 4 times of amounts, decocted 1 hour, and filtered; With the water of 7 times of amounts, decocted 2.5 hours for the second time, filter;
C. above-mentioned twice filtrate is merged, be concentrated into thick paste, subtract and be compressed to relative density 1.28 (50 ℃);
D. in above-mentioned thick paste, add Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, Scorpio five kinds of Chinese medicine coarse powder, mixing, drying is ground into fine powder, uses water pill, and 65 ℃ of dryings get plain ball;
E. use 4g Cortex Eucommiae carbon with plain ball coating, polishing, ball gets product.The heavy 5g of per 30 balls.
Embodiment two
A kind of Chinese medicine (Testudinis dragon apoplexy ball) for the treatment of apoplexy of the present invention is to be made of by weight following preferred feedstock: Radix Rehmanniae Preparata: the Radix Paeoniae Alba: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Radix Achyranthis Bidentatae: Os Draconis: Carapax et Plastrum Testudinis: Radix Salviae Miltiorrhizae: Semen Persicae: Radix Paeoniae Rubra: Pheretima: Rhizoma Acori Graminei: Concretio Silicea Bambusae: Fructus Chaenomelis: Herba Lycopodii: Semen Coicis: Ramulus Mori: Retinervus Luffae Fructus: Scorpio: Cortex Eucommiae carbon=12: 12: 7: 7: 7: 10: 7: 12: 7: 7: 7: 7: 12: 10: 8: 12: 12: 7: 5: 3.
Preparation technology of the present invention following (Fig. 1):
A. above 20 flavor medicines are got Concretio Silicea Bambusae 48g, Rhizoma Acori Graminei 28g, Semen Coicis 48g, Pheretima 28g, Scorpio 20g is ground into coarse powder;
B. get Radix Rehmanniae Preparata 48g, Radix Paeoniae Alba 48g, Radix Angelicae Sinensis 28g, Rhizoma Chuanxiong 28g, Radix Achyranthis Bidentatae 28g, Os Draconis 40g, Carapax et Plastrum Testudinis 28g, Radix Salviae Miltiorrhizae 48g, Semen Persicae 28g, Radix Paeoniae Rubra 28g, Fructus Chaenomelis 40g, Herba Lycopodii 32g, Ramulus Mori 48g Retinervus Luffae Fructus 28g decocts with water secondary, for the first time with the water of 4 times of amounts, decocted 1 hour, and filtered; With the water of 7 times of amounts, decocted 2.5 hours for the second time, filter;
C. above-mentioned twice filtrate is merged, be concentrated into thick paste, subtract and be compressed to relative density 1.30 (60 ℃);
D. in above-mentioned thick paste, add Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, Scorpio five kinds of Chinese medicine coarse powder, mixing, drying is ground into fine powder, uses water pill, and 95 ℃ of dryings get plain ball;
E. use Cortex Eucommiae carbon with plain ball coating, polishing, ball gets product.The heavy 5g of per 30 balls.
Embodiment three
A kind of Chinese medicine (Testudinis dragon apoplexy ball) for the treatment of apoplexy of the present invention is to be made of by weight following preferred feedstock: Radix Rehmanniae Preparata: the Radix Paeoniae Alba: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Radix Achyranthis Bidentatae: Os Draconis: Carapax et Plastrum Testudinis: Radix Salviae Miltiorrhizae: Semen Persicae: Radix Paeoniae Rubra: Pheretima: Rhizoma Acori Graminei: Concretio Silicea Bambusae: Fructus Chaenomelis: Herba Lycopodii: Semen Coicis: Ramulus Mori: Retinervus Luffae Fructus: Scorpio: Cortex Eucommiae carbon=10: 10: 5: 5: 5: 8: 5: 10: 5: 5: 5: 5: 10: 8: 6: 10: 10: 5: 3: 2.
Preparation technology of the present invention following (Fig. 1):
A. above 20 flavor medicines are got Concretio Silicea Bambusae 40g, Rhizoma Acori Graminei 20g, Semen Coicis 40g, Pheretima 20g, Scorpio 12g is ground into coarse powder;
B. get Radix Rehmanniae Preparata 40g, Radix Paeoniae Alba 40g, Radix Angelicae Sinensis 20g, Rhizoma Chuanxiong 20g, Radix Achyranthis Bidentatae 20g, Os Draconis 32g, Carapax et Plastrum Testudinis 20g, Radix Salviae Miltiorrhizae 40g, Semen Persicae 20g, Radix Paeoniae Rubra 20g, Fructus Chaenomelis 32g, Herba Lycopodii 24g, Ramulus Mori 40g, Retinervus Luffae Fructus 20g decoct with water secondary, for the first time with the water of 6 times of amounts, decocted 2 hours, and filtered; With the water of 5 times of amounts, decocted 1.5 hours for the second time, filter;
C. above-mentioned twice filtrate is merged, be concentrated into thick paste, subtract and be compressed to relative density 1.29 (55 ℃);
D. in above-mentioned thick paste, add Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, Scorpio five kinds of Chinese medicine coarse powder, mixing, drying is ground into fine powder, uses water pill, and 85 ℃ of dryings get plain ball;
E. use Cortex Eucommiae carbon with plain ball coating, polishing, promptly get 1000 ball finished product balls.The heavy 5g of per 30 balls.
Embodiment four
A kind of Chinese medicine (Testudinis dragon apoplexy ball) for the treatment of apoplexy of the present invention is to be made of by weight following preferred feedstock: Radix Rehmanniae Preparata: the Radix Paeoniae Alba: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Radix Achyranthis Bidentatae: Os Draconis: Carapax et Plastrum Testudinis: Radix Salviae Miltiorrhizae: Semen Persicae: Radix Paeoniae Rubra: Pheretima: Rhizoma Acori Graminei: Concretio Silicea Bambusae: Fructus Chaenomelis: Herba Lycopodii: Semen Coicis: Ramulus Mori: Retinervus Luffae Fructus: Scorpio: Cortex Eucommiae carbon=11: 11: 6: 6: 6: 9: 6: 11: 6: 6: 6: 6: 11: 9: 7: 11: 11: 6: 4: 2.
Preparation technology of the present invention following (Fig. 1):
A. above 20 flavor medicines are got Concretio Silicea Bambusae 44g, Rhizoma Acori Graminei 24g, Semen Coicis 44g, Pheretima 24g, Scorpio 16g is ground into coarse powder;
B. get Radix Rehmanniae Preparata 44g, Radix Paeoniae Alba 44g, Radix Angelicae Sinensis 24g, Rhizoma Chuanxiong 24g, Radix Achyranthis Bidentatae 24g, Os Draconis 36g, Carapax et Plastrum Testudinis 24g, Radix Salviae Miltiorrhizae 44g, Semen Persicae 24g, Radix Paeoniae Rubra 24g, Fructus Chaenomelis 36g, Herba Lycopodii 28g, Ramulus Mori 44g Retinervus Luffae Fructus 24g decocts with water secondary, for the first time with the water of 5 times of amounts, decocted 1.5 hours, and filtered; With the water of 7 times of amounts, decocted 2 hours for the second time, filter;
C. above-mentioned twice filtrate is merged, be concentrated into thick paste, subtract and be compressed to relative density 1.29 (60 ℃);
D. in above-mentioned thick paste, add Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, Scorpio five kinds of Chinese medicine coarse powder, mixing, drying is ground into fine powder, uses water pill, and 85 ℃ of dryings get plain ball;
E. use 8g Cortex Eucommiae carbon with plain ball coating, polishing, ball gets product.The heavy 5g of per 30 balls.
Embodiment five
A kind of Chinese medicine (Testudinis dragon apoplexy ball) for the treatment of apoplexy of the present invention is to be made of by weight following preferred feedstock: Radix Rehmanniae Preparata: the Radix Paeoniae Alba: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Radix Achyranthis Bidentatae: Os Draconis: Carapax et Plastrum Testudinis: Radix Salviae Miltiorrhizae: Semen Persicae: Radix Paeoniae Rubra: Pheretima: Rhizoma Acori Graminei: Concretio Silicea Bambusae: Fructus Chaenomelis: Herba Lycopodii: Semen Coicis: Ramulus Mori: Retinervus Luffae Fructus: Scorpio: Cortex Eucommiae carbon=9: 9: 4: 4: 4: 7: 4: 9: 4: 4: 4: 4: 9: 7: 5: 9: 9: 4: 1: 1.
Its preparation technology following (Fig. 1):
A. above 20 flavor medicines are got Concretio Silicea Bambusae 36g, Rhizoma Acori Graminei 16g, Semen Coicis 36g, Pheretima 16g, Scorpio 4g is ground into coarse powder;
B. get Radix Rehmanniae Preparata 36g, Radix Paeoniae Alba 36g, Radix Angelicae Sinensis 16g, Rhizoma Chuanxiong 16g, Radix Achyranthis Bidentatae 16g, Os Draconis 28g, Carapax et Plastrum Testudinis 16g, Radix Salviae Miltiorrhizae 36g, Semen Persicae 16g, Radix Paeoniae Rubra 16g, Fructus Chaenomelis 28g, Herba Lycopodii 20g, Ramulus Mori 36g, Retinervus Luffae Fructus 16g decoct with water secondary, for the first time with the water of 4 times of amounts, decocted 1 hour, and filtered; With the water of 7 times of amounts, decocted 2.5 hours for the second time, filter;
C. above-mentioned twice filtrate is merged, be concentrated into thick paste, subtract and be compressed to relative density 1.28 (50 ℃);
D. in above-mentioned thick paste, add Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, Scorpio five kinds of Chinese medicine coarse powder, mixing, drying is ground into fine powder, uses water pill, and 65 ℃ of dryings get plain ball;
E. use 4g Cortex Eucommiae carbon with plain ball coating, polishing, ball gets product.The heavy 5g of per 30 balls.
Claims (4)
1, a kind of Chinese medicine for the treatment of apoplexy is characterized in that wherein making raw materials of effective components consists of by weight: Radix Rehmanniae Preparata: the Radix Paeoniae Alba: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Radix Achyranthis Bidentatae: Os Draconis: Carapax et Plastrum Testudinis: Radix Salviae Miltiorrhizae: Semen Persicae: Radix Paeoniae Rubra: Pheretima: Rhizoma Acori Graminei: Concretio Silicea Bambusae: Fructus Chaenomelis: Herba Lycopodii: Semen Coicis: Ramulus Mori: Retinervus Luffae Fructus: Scorpio: Cortex Eucommiae carbon=8-12: 8-12: 3-7: 3-7: 3-7: 6-10: 3-7: 8-12: 3-7: 3-7: 3-7: 3-7: 8-12: 6-10: 4-8: 8-12: 8-12: 3-7: 1-5: 1-3.
2, the Chinese medicine of treatment apoplexy according to claim 1 is characterized in that wherein making raw materials of effective components consists of by weight: Radix Rehmanniae Preparata: the Radix Paeoniae Alba: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Radix Achyranthis Bidentatae: Os Draconis: Carapax et Plastrum Testudinis: Radix Salviae Miltiorrhizae: Semen Persicae: Radix Paeoniae Rubra: Pheretima: Rhizoma Acori Graminei: Concretio Silicea Bambusae: Fructus Chaenomelis: Herba Lycopodii: Semen Coicis: Ramulus Mori: Retinervus Luffae Fructus: Scorpio: Cortex Eucommiae carbon=10: 10: 5: 5: 5: 8: 5: 10: 5: 5: 5: 5: 10: 8: 6: 10: 10: 5: 3: 2.
3, the preparation method of Chinese medicine of a kind of claim 1 or 2 described treatment apoplexy is characterized in that it comprises the steps:
A. above 20 flavor medicines are got the Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, the Scorpio that meet the above-mentioned raw materials proportioning and are ground into coarse powder;
B. get the Radix Rehmanniae Preparata, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Achyranthis Bidentatae, Os Draconis, Carapax et Plastrum Testudinis, Radix Salviae Miltiorrhizae, Semen Persicae, Radix Paeoniae Rubra, Fructus Chaenomelis, Herba Lycopodii, Ramulus Mori, Retinervus Luffae Fructus ten four Chinese medicines that meet the above-mentioned raw materials proportioning and decoct with water secondary, filter to get filtrate at every turn;
C. the filtrate with above-mentioned each decoction gained merges, and is concentrated into thick paste, and relative density is 1.28-1.30 when 50-60 ℃ of temperature;
D. in above-mentioned thick paste, add Concretio Silicea Bambusae, Rhizoma Acori Graminei, Semen Coicis, Pheretima, Scorpio five kinds of Chinese medicine coarse powder, mixing, drying is ground into fine powder, uses water pill, 65-95 ℃ of drying;
E. use the polishing of Cortex Eucommiae carbon coating, promptly.
4, a kind of preparation method of Chinese medicine for the treatment of apoplexy according to claim 3 is characterized in that described b decocts with water secondary in the step, 6 times of water gagings for the first time, 2 hours; 5 times of water gagings for the second time, 1.5 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101051981A CN1247247C (en) | 2003-11-26 | 2003-11-26 | Apoplexy treating Chinese traditional medicine and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101051981A CN1247247C (en) | 2003-11-26 | 2003-11-26 | Apoplexy treating Chinese traditional medicine and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1543992A CN1543992A (en) | 2004-11-10 |
| CN1247247C true CN1247247C (en) | 2006-03-29 |
Family
ID=34333659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101051981A Expired - Lifetime CN1247247C (en) | 2003-11-26 | 2003-11-26 | Apoplexy treating Chinese traditional medicine and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1247247C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102861227B (en) * | 2012-10-18 | 2014-10-15 | 张淼 | Traditional Chinese medicine composition for treating suppurative meningitis sequelae and preparation method of traditional Chinese medicine composition |
-
2003
- 2003-11-26 CN CNB2003101051981A patent/CN1247247C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1543992A (en) | 2004-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101032580A (en) | Medicine for treating rheumatic diseases | |
| CN1245189C (en) | Composition for strengthening body resistance and restoring and function, strengthening spleen and kidney, relieving metal stress and promoting blood circulation to remove blood stasis | |
| CN101032560A (en) | Chinese medicine composition for treating somnipathy and preparing method thereof | |
| CN1194735C (en) | Chinese medicine for treating hyperplasia of mammary glands | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1247247C (en) | Apoplexy treating Chinese traditional medicine and its preparation | |
| CN101028325A (en) | Medicinal composition containing sailonggu, and its preparation and quality control | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1264537C (en) | Capsule | |
| CN1136880C (en) | Combined Chinese and Western medicine for treating bronchial asthma | |
| CN1270767C (en) | Medicine for treating vasculitis, scleriasis and arteriosclerosis type lower limb vascular occlusion | |
| CN1698878A (en) | A pharmaceutical composition for invigorating the kidney, its preparation method and new application | |
| CN1301129C (en) | A medicine for treating wind-cold-damp arthralgia and weakness of muscles and bones | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN101062374A (en) | Method for preparing Chinese traditional combination capsule for treating cancer and the product thereof | |
| CN1222305C (en) | Chinese medicine for treating liver-kidney insufficiency, qi and yin vacuity and its preparation method | |
| CN1820770A (en) | Chinese medicine composition for treating apoplexy and its preparing method | |
| CN1314415C (en) | Skin disease treating Chinese traditional medicine | |
| CN1250278C (en) | Oral medicine for treating dementia and feeblemindedpess | |
| CN1290547C (en) | Traditional Chinese medicine for treating and preventing high blood pressure and its preparation technology | |
| CN1840087A (en) | King solomonseal- and fleece-flower root-containing Chinese medicinal formulation for treating chronic fatigue syndrome and its preparation method | |
| CN1565528A (en) | Medicine for treating ovary cyst and its preparing process | |
| CN1651017A (en) | Pharmaceutical composition and preparation method for treating cervical spondylosis | |
| CN1413653A (en) | Chinese drugs for treating cardiovascular and cerebrovascular system disease and its preparation method | |
| CN1316993C (en) | Medicine for treating cerebral infarction, coronary heart disease and angina pectoris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENYANG HONGYAO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHENYANG CHINESE MEDICINE PHARMACEUTICAL CO., LTD. Effective date: 20080404 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080404 Address after: Liaoning province Shenyang City District City Road No. 2 Patentee after: SHENYANG HONGYAO PHARMACEUTICAL Co.,Ltd. Address before: Liaoning province Shenyang City District City Road No. 2 Patentee before: SHENYANG CHINESE MEDICINE PHAR |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20111228 Address after: 110044 Liaoning Province, Shenyang City District City Road No. 2 Patentee after: SHENYANG HONGYAO PHARMACEUTICAL Co.,Ltd. Address before: 110044 Liaoning Province, Shenyang City District City Road No. 2 Patentee before: SHENYANG HONGYAO PHARMACEUTICAL Co.,Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140506 Address after: 110044 Liaoning Province, Shenyang City District City Road No. 2 Patentee after: SHENYANG HONGYAO GROUP Co.,Ltd. Address before: 110044 Liaoning Province, Shenyang City District City Road No. 2 Patentee before: SHENYANG HONGYAO PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060329 |
|
| CX01 | Expiry of patent term |